What is Allogene Therapeutics, Inc. (ALLO) stock price today?

Allogene Therapeutics, Inc. (ALLO) is currently trading at $1.31, down 2.24% today.

What is ALLO P/E ratio?

Allogene Therapeutics, Inc.'s P/E ratio is -2.24. A negative P/E means the company reported a net loss over the last twelve months, so P/E is not a meaningful valuation measure for it right now.

What is ALLO return on equity (ROE)?

Allogene Therapeutics, Inc.'s return on equity (ROE) is -50.04%. ROE measures net income relative to shareholders' equity. A negative ROE means the company reported a net loss over the period.

What is Allogene Therapeutics, Inc.'s market cap?

Allogene Therapeutics, Inc. has a market capitalization of $452.59M.

NASDAQ · Biotechnology

Allogene Therapeutics, Inc. (ALLO) Stock

$1.31 -2.24% NASDAQ: ALLO Healthcare

Valuation

Metric	Value
Price	$1.31
Market Cap	$452.59M
P/E Ratio	-2.24
P/B Ratio	1.13
P/S Ratio	111.58
EPS (TTM)	$-0.87
52-Week High	$4.46
52-Week Low	$1.04
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-50.04%
ROA	-30.08%
ROCE	-34.79%
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Debt/Equity	0.16
Current Ratio	7.82

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$114.0M	$0	$0	$0	$0
Operating Profit	$-180.0M	$-336.0M	$-328.0M	$-273.0M	$-207.0M
Net Profit	$-182.0M	$-340.0M	$-327.0M	$-258.0M	$-191.0M
EPS	$-1.34	$-2.38	$-2.09	$-1.32	$-0.87
Op Margin	-157.9%	-215087.2%	-344986.3%	-1241813.6%	—

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$1.1B	$822.0M	$643.0M	$549.0M	$416.0M
Total Liabilities	$126.0M	$155.0M	$131.0M	$127.0M	$123.0M
Cash	$173.0M	$62.0M	$83.0M	$75.0M	$52.0M
Borrowings	$73.0M	$101.0M	$95.0M	$91.0M	$83.0M

Latest News

Allogene Therapeutics Announces Journal of Clinical Oncology Publication of Phase 1 Results of ALLO-316 Highlighting First Durable Remissions Following Allogeneic CAR T for Treatment of Metastatic Solid Tumors GlobeNewswire · Jul 15, 2026 Kyverna Therapeutics Sinks 13%: Here’s Why 24/7 Wall St. · Jul 10, 2026 Imviva Biotech Granted FDA IDE Authorization for Cancer Treatment Trial Exec Edge · Jun 30, 2026 Allogene Therapeutics (ALLO) Stock Gets Fair Value Boost After Split Analyst Revisions Simply Wall St. · Jun 28, 2026 How Allogene Therapeutics (ALLO) Is Expanding Its Off-the-Shelf CAR T Platform Across Cancer and Autoimmune Disease Insider Monkey · Jun 17, 2026

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$-185.0M	$-221.0M	$-238.0M	$-200.0M	$-149.0M
Investing Cash Flow	$142.0M	$101.0M	$162.0M	$75.0M	$95.0M
Financing Cash Flow	$0	$0	$5.0M	$2.0M	$7.0M
Net Cash Flow	$-9.0M	$-111.0M	$21.0M	$-8.0M	$-24.0M
Free Cash Flow	$-206.0M	$-226.0M	$-239.0M	$-201.0M	$-150.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	-0.04
EV / EBITDA	-3.60
FCF Yield	-19.82%
Quick Ratio	10.72
Interest Coverage	-138.71
Return 1Y	9.64%
Return 3Y	-63.16%
Return 5Y	-91.72%

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
ATRAAtara Biotherapeutics, Inc.	$9.18	-4.87%	-7.94	$92.15M	0.00%
AUTLAutolus Therapeutics plc	$1.46	-13.61%	-1.35	—	0.00%
CELUCelularity Inc.	$1.25	-6.02%	-0.46	$40.56M	0.00%
CLLSCellectis S.A.	$2.81	-2.26%	-4.14	$282.17M	0.00%
CRBUCaribou Biosciences, Inc.	$0.47	+1.12%	-1.13	$50.38M	0.00%

About Allogene Therapeutics, Inc.

Allogene Therapeutics, Inc. is led by CEO David D. Chang, publicly traded since 2018.

Allogene Therapeutics, Inc. (ALLO) stock trades at $1.31 with a market capitalization of $452.59M. The stock is valued at a negative price-to-earnings (P/E) ratio of -2.24, reflecting a net loss over the last twelve months, price-to-book of 1.13, price-to-sales of 111.58. Over the past 52 weeks the stock has ranged between $1.04 and $4.46, and currently trades 70.6% below its 52-week high.

On profitability, Allogene Therapeutics, Inc. generates a return on equity (ROE) of -50.04% (negative, reflecting a net loss), return on capital employed of -34.79%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1257.03 +0.43% JNJ Johnson & Johnson $255.56 +0.90% ABBV AbbVie Inc. $285.42 +0.71% UNH UnitedHealth Group Incorporated Common Stock (DE) $401.43 -1.29% MRK Merck & Company, Inc. Common Stock (new) $145.97 +0.53% NVS Novartis AG $150.62 +0.16% AZN AstraZeneca PLC $165.41 -0.76% TMO Thermo Fisher Scientific Inc $690.00 -0.93% AMGN Amgen Inc. $432.49 -0.35% GILD Gilead Sciences, Inc. $156.19 -0.75% ABT Abbott Laboratories $104.88 +0.19% NVO Novo Nordisk A/S $38.83 -0.99%

Related stock screens

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks Nasdaq High ROE Stocks All stock screens

Run Stock Screener Investing Guides

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.